Liposarcoma Clinical Trials 2024

What are the top hospitals conducting liposarcoma research?

When it comes to clinical trials for liposarcoma, several leading hospitals are making significant strides in research and treatment options. In New york City, Memorial Sloan Kettering Cancer Center leads the way with nine active trials focused on this rare form of cancer that arises from fat cells. With a total of 12 completed trials since their first recorded investigation in 2010, they have demonstrated an unwavering commitment to advancing knowledge and improving outcomes for liposarcoma patients.

Meanwhile, the Dana-Farber Cancer Institute in Boston has also been at the forefront of liposarcoma research. Their ongoing efforts include six active clinical trials aimed at finding innovative treatments for this aggressive disease. Since conducting their inaugural trial in 1997, they have accumulated a wealth of experience with a total of 14 studies conducted.

In Houston, MD Anderson Cancer Center is contributing to the fight against liposarcoma with five ongoing trials dedicated to understanding this complex cancer better. Despite joining the effort relatively recently in 2012 with their first recorded trial, MD Anderson's impact cannot be underestimated as they continue to expand our knowledge and potential treatment options.

Similarly making great strides is Moffitt Cancer Center located in Tampa where they too have commenced five ongoing investigations regarding discovering newer solutions combating Liposarcomas since its establishment recording initial examination back until two thousand fourteen; being partakers actively contributes more towards bringing light upon such cases.

These top hospitals' dedication reflects not only medical excellence but also compassion for individuals affected by liposarcoma—a condition that poses unique challenges due to its rarity and complexity. By collaborating on these vital clinical trials across diverse locations within the United States, these institutions collectively work towards uncovering new breakthroughs and ensuring innovation doesn't halt when fighting Liposacromas

Which are the best cities for liposarcoma clinical trials?

When it comes to liposarcoma clinical trials, several cities stand out as key destinations for cutting-edge research. Boston, Massachusetts leads the pack with 22 active trials exploring treatments like PF-07220060, Pembrolizumab, and CAB-AXL-ADC. New york, New York closely follows with 21 ongoing studies focusing on CAB-AXL-ADC, Abemaciclib, and RAIN-32. Houston, Texas is another notable city offering 17 active trials investigating approaches such as Radiation Therapy and CATCH T cells. Lastly, Los Angeles in California and Nashville in Tennessee offer promising opportunities for patients with 15 and 11 active trials respectively. These cities serve as epicenters of liposarcoma clinical research where patients can access innovative treatment options that may shape the future of care for this rare cancer type.

Which are the top treatments for liposarcoma being explored in clinical trials?

In the realm of liposarcoma, clinical trials have shed light on several top treatments that display immense potential. Among these are radiation therapy, which is currently being explored in two active trials and has a track record of five all-time liposarcoma trials since its debut in 2006. Another contender is seclidemstat, making waves with two ongoing trials and two all-time liposarcoma studies since its listing in 2018. Additionally, abemaciclib showcases promise as it participates in two active trials alongside its inclusion in two past liposarcoma studies after being listed for the first time in 2016. Lastly, an exciting newcomer to the scene is CATCH T cells—a treatment under investigation with one active trial and one all-time liposarcoma study recorded thus far since its introduction this year (2021). Through continued exploration, researchers aim to revolutionize treatment options for individuals battling this challenging cancer type.

What are the most recent clinical trials for liposarcoma?

Exciting advancements are being made in the field of liposarcoma research, with several recent clinical trials offering hope for improved treatment options. One notable trial is SPH4336, a Phase 2 study that explores its effectiveness specifically for liposarcoma patients. Additionally, CARE T cells have shown promising results in Phase 1 trials as a potential therapy for this type of cancer. Another Phase 2 trial focuses on participants with dedifferentiated liposarcoma/DDLPS and aims to evaluate novel treatment approaches. Furthermore, a Phase 1 single-agent therapy dose expansion trial holds promise for enhancing patient outcomes. Lastly, CAR-GPC3 T Cells show potential benefits in both Phase 1 and Phase 2 studies conducted since May 2022. These ongoing trials offer renewed hope to individuals battling liposarcoma by paving the way toward more effective treatments.

What liposarcoma clinical trials were recently completed?

Recently, several clinical trials investigating potential treatments for liposarcoma have reached completion, marking important milestones in the pursuit of improved therapies. In September 2018, M.D. Anderson Cancer Center successfully concluded a trial evaluating Autologous NY-ESO-1-specific CD8-positive T Lymphocytes. Preceding that, in March 2017, OHSU Knight Cancer Institute wrapped up a pharmacological study focused on this challenging cancer type. Additionally, GlaxoSmithKline's trial examining letetresgene autoleucel (GSK3377794) was completed in December 2016. These significant research efforts pave the way for advancements against liposarcoma and offer hope to patients battling this complex disease.